Charles River Laboratories International Inc.

257.74+9.53+3.84%Vol 316.32K1Y Perf -27.65%
Feb 2nd, 2023 12:03 DELAYED
BID257.52 ASK257.89
Open251.04 Previous Close248.21
Pre-Market- After-Market-
 - -%  - -
Target Price
283.25 
Analyst Rating
Moderate Buy 1.55
Potential %
9.32 
Finscreener Ranking
★★★     49.88
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     49.11
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★     58.41
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
45.33 
Earnings Rating
Sell
Market Cap13.11B 
Earnings Date
15th Feb 2023
Alpha0.01 Standard Deviation0.09
Beta1.26 

Today's Price Range

250.00259.88

52W Range

181.36349.84

5 Year PE Ratio Range

18.9063.90

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
1.60%
1 Month
13.91%
3 Months
15.05%
6 Months
1.87%
1 Year
-27.65%
3 Years
60.57%
5 Years
141.12%
10 Years
493.95%

TickerPriceChg.Chg.%
CRL257.749.52503.84
AAPL149.764.32592.97
GOOG107.636.20006.11
MSFT261.318.56003.39
XOM111.75-2.9950-2.61
WFC47.340.30900.66
JNJ164.20-0.7200-0.44
FB196.640.99000.51
GE82.870.55000.67
JPM139.32-0.2700-0.19
 
ProfitabilityValueIndustryS&P 500US Markets
37.30
15.30
23.00
14.70
10.55
RevenueValueIndustryS&P 500US Markets
2.88B
56.53
13.23
14.96
Earnings HistoryEstimateReportedSurprise %
Q03 20222.512.634.78
Q02 20222.742.771.09
Q01 20222.712.751.48
Q04 20212.422.492.89
Q03 20212.572.705.06
Q02 20212.392.619.20
Q01 20212.192.5315.53
Q04 20202.122.3912.74
Earnings Per EndEstimateRevision %Trend
12/2022 QR2.74-2.49Negative
12/2022 FY10.880.93Positive
3/2023 QR2.63-10.54Negative
12/2023 FY11.39-6.94Negative
Next Report Date15th Feb 2023
Estimated EPS Next Report2.75
Estimates Count7
EPS Growth Next 5 Years %14.00
Volume Overview
Volume316.32K
Shares Outstanding50.88K
Shares Float39.37M
Trades Count7.28K
Dollar Volume81.38M
Avg. Volume459.41K
Avg. Weekly Volume315.99K
Avg. Monthly Volume469.36K
Avg. Quarterly Volume592.88K

Charles River Laboratories International Inc. (NYSE: CRL) stock closed at 248.21 per share at the end of the most recent trading day (a 2.04% change compared to the prior day closing price) with a volume of 300.96K shares and market capitalization of 13.11B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 18400 people. Charles River Laboratories International Inc. CEO is James C. Foster.

The one-year performance of Charles River Laboratories International Inc. stock is -27.65%, while year-to-date (YTD) performance is 13.91%. CRL stock has a five-year performance of 141.12%. Its 52-week range is between 181.36 and 349.84, which gives CRL stock a 52-week price range ratio of 45.33%

Charles River Laboratories International Inc. currently has a PE ratio of 25.90, a price-to-book (PB) ratio of 4.26, a price-to-sale (PS) ratio of 4.03, a price to cashflow ratio of 18.40, a PEG ratio of 2.32, a ROA of 6.53%, a ROC of 8.04% and a ROE of 18.64%. The company’s profit margin is 10.55%, its EBITDA margin is 23.00%, and its revenue ttm is $2.88 Billion , which makes it $56.53 revenue per share.

Of the last four earnings reports from Charles River Laboratories International Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.75 for the next earnings report. Charles River Laboratories International Inc.’s next earnings report date is 15th Feb 2023.

The consensus rating of Wall Street analysts for Charles River Laboratories International Inc. is Moderate Buy (1.55), with a target price of $283.25, which is +9.32% compared to the current price. The earnings rating for Charles River Laboratories International Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Charles River Laboratories International Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Charles River Laboratories International Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.26, ATR14 : 7.99, CCI20 : 84.47, Chaikin Money Flow : 0.25, MACD : 5.94, Money Flow Index : 56.89, ROC : 6.70, RSI : 60.51, STOCH (14,3) : 77.55, STOCH RSI : 0.83, UO : 55.97, Williams %R : -22.45), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Charles River Laboratories International Inc. in the last 12-months were: David R. Smith (Option Excercise at a value of $1 224 594), David R. Smith (Sold 8 965 shares of value $2 532 920 ), George E. Massaro (Sold 148 shares of value $34 177 ), James C. Foster (Option Excercise at a value of $4 741 630), James C. Foster (Sold 57 407 shares of value $17 084 160 ), Joseph W. LaPlume (Option Excercise at a value of $766 181), Joseph W. LaPlume (Sold 9 077 shares of value $2 162 302 ), Michael Gunnar Knell (Option Excercise at a value of $93 486), Michael Gunnar Knell (Sold 855 shares of value $212 544 ), Richard F. Wallman (Buy at a value of $328 350), Richard F. Wallman (Sold 7 200 shares of value $2 108 413 ), Shannon M. Parisotto (Option Excercise at a value of $249 186), Shannon M. Parisotto (Sold 2 279 shares of value $569 522 ), William D. Barbo (Option Excercise at a value of $350 435), William D. Barbo (Sold 3 205 shares of value $704 814 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (72.73 %)
8 (80.00 %)
8 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (27.27 %)
2 (20.00 %)
2 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.55
Strong Buy
1.40
Strong Buy
1.40

Charles River Laboratories International Inc.

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

CEO: James C. Foster

Telephone: +1 781 222-6000

Address: 251 Ballardvale Street, Wilmington 01887, MA, US

Number of employees: 18 400

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

62%38%

Bearish Bullish

61%39%

TipRanks News for CRL

Mon, 10 Oct 2022 14:24 GMT FDA Demands More Data for Supernus SPN-830 NDA Filing

- TipRanks. All rights reserved.

News

Stocktwits